Sulzberger Capital Advisors Inc. Reduces Position in Johnson & Johnson (NYSE:JNJ)

Sulzberger Capital Advisors Inc. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 11.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,780 shares of the company’s stock after selling 350 shares during the quarter. Johnson & Johnson makes up approximately 0.6% of Sulzberger Capital Advisors Inc.’s portfolio, making the stock its 27th largest holding. Sulzberger Capital Advisors Inc.’s holdings in Johnson & Johnson were worth $461,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Tallon Kerry Patrick bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $290,000. Capital & Planning LLC lifted its holdings in shares of Johnson & Johnson by 13.6% in the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company’s stock worth $221,000 after buying an additional 183 shares in the last quarter. Brighton Jones LLC lifted its holdings in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after buying an additional 6,332 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth about $85,886,000. Finally, Mather Group LLC. lifted its holdings in shares of Johnson & Johnson by 1.8% in the fourth quarter. Mather Group LLC. now owns 131,844 shares of the company’s stock worth $19,067,000 after buying an additional 2,315 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.9%

Shares of NYSE JNJ opened at $155.02 on Friday. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm’s 50 day simple moving average is $153.59 and its two-hundred day simple moving average is $153.68. The stock has a market capitalization of $372.99 billion, a P/E ratio of 23.31, a PEG ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $21.89 billion for the quarter, compared to analysts’ expectations of $21.65 billion. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a $1.30 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.35%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 57.84%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on JNJ. Barclays lowered their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a report on Thursday, April 17th. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Raymond James lowered their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a report on Monday, April 14th. Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Finally, Leerink Partnrs cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.